Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6197007 | 0.95 | CHRM2 (0.81) | CHRM2CHRM1 | |
| SCHEMBL6195475 | 0.95 | CHRM2 (0.81) | CHRM2CHRM1 | |
| SCHEMBL6198562 | 0.94 | CHRM2 (1.00) | CHRM2CHRM1 | |
| SCHEMBL21802372 | 0.91 | CHRM2 (0.86) | CHRM2CHRM1 | |
| SCHEMBL6198924 | 0.89 | CHRM2 (0.81) | CHRM2CHRM1 | |
| SCHEMBL6198955 | 0.89 | CHRM2 (0.81) | CHRM2CHRM1 | |
| SCHEMBL6197795 | 0.89 | CHRM2 (1.00) | CHRM2CHRM1 | |
| SCHEMBL6193605 | 0.88 | CHRM2 (0.74) | CHRM2CHRM1 | |
| SCHEMBL6194677 | 0.88 | CHRM2 (0.74) | CHRM2CHRM1 | |
| SCHEMBL6198189 | 0.87 | CHRM2 (0.78) | CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260147006-A1 | SCREENING METHOD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-28 | — | — | US | disclosed |
| US-12298319-B2 | Method for measuring alpha value of muscarinic M1 receptor positive allosteric modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-05-13 | — | — | US | disclosed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20200182850-A1 | SCREENING METHOD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200182850-A1 | SCREENING METHOD | CHRM1, CHRM2, CHRM4 | CHRM2 2/4885CHRM1 1/4885 |
| US-12298319-B2 | Method for measuring alpha value of muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM2, CHRM4 | CHRM2 2/4885CHRM1 1/4885 |
| US-20260147006-A1 | SCREENING METHOD | CHRM1, CHRM4, CHRM5 | CHRM2 4/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.